Chemical Structure (Ampyra 01)
Ampyra Tablet, Film Coated, Extended Release
Product Images NDC 0259-5010
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Ampyra (NDC 0259-5010). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Merz Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 1 (Ampyra 02)
Average Percent Increase in Walking Speed from Baseline:
10% with Placebo (n=72)
210% with AMPYRA 10 mg bid (n=229)*
Figure 2 (Ampyra 03)
This text provides information about patients shown as percentages, different treatments (a placebo and ApTRA Dmg bid), and the average percent increase in walking speed from baseline. The data seems to be a comparison between different treatment options.*
Principal Display Panel (10 mg Tablet Bottle Label)
This is a product label for NDC 0259-5010-60, which contains Amprya (dalfampridine) Extended Release Tablets. The label indicates that there are 60 tablets in the package. Additionally, the text suggests that a pharmacist should dispense the accompanying medication guide to each patient. The manufacturer appears to be Acorda Therapeutics, LLC from Canada.*
Crcl-eqn-102716.jpg (Crcl Eqn 102716)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
